Genetics, stomach contents at injection time, and individual receptor sensitivity influence when you perceive the medication's effects
Nausea, constipation, and mild headache are typical early side effects, usually resolving within 23 weeks
It gives you ongoing access to your care team, guidance along the way, and support as your plan evolves , which are all tailored to you, not pulled from a generic package
AOD-9604 holds no Health Canada human or veterinary use authorization, and Health Canada has stated in public advisories that unauthorized injectable peptide products are illegal regardless of the 'for research use only' labelling on the container
Long-term side effects havent been reported with the drug at this time
Food and Drug Administration (FDA): Mounjaro (tirzepatide), Eli Lilly & Co.s groundbreaking new medication and the first and only dual GIP and GLP-1 receptor agonist